Which has higher valuation & earnings, ELVN or ABVX?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is ELVN or ABVX more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Abivax N/A -99.02% -70.26%

Does the media prefer ELVN or ABVX?

In the previous week, Abivax had 23 more articles in the media than Enliven Therapeutics. MarketBeat recorded 27 mentions for Abivax and 4 mentions for Enliven Therapeutics. Abivax's average media sentiment score of 0.06 beat Enliven Therapeutics' score of -0.03 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 4 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Neutral

Is ELVN or PRAX more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Praxis Precision Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Praxis Precision Medicines N/A -43.02% -40.22%

Does the media refer more to ELVN or PRAX?

In the previous week, Praxis Precision Medicines had 22 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 4 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of -0.03 beat Praxis Precision Medicines' score of -0.10 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 3 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CYTK or ELVN?

In the previous week, Cytokinetics had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 9 mentions for Cytokinetics and 4 mentions for Enliven Therapeutics. Cytokinetics' average media sentiment score of 0.10 beat Enliven Therapeutics' score of -0.03 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELVN or KRYS?

In the previous week, Krystal Biotech had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 5 mentions for Krystal Biotech and 4 mentions for Enliven Therapeutics. Krystal Biotech's average media sentiment score of 0.43 beat Enliven Therapeutics' score of -0.03 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELVN or IBRX?

In the previous week, ImmunityBio had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 8 mentions for ImmunityBio and 4 mentions for Enliven Therapeutics. ImmunityBio's average media sentiment score of 0.15 beat Enliven Therapeutics' score of -0.03 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Enliven Therapeutics (ELVN) Competitors

$34.71 -0.78 (-2.20%)

Closing price 04:00 PM Eastern

Extended Trading

$34.74 +0.03 (+0.10%)

As of 04:15 PM Eastern

Compare

ELVN vs. ABVX, PRAX, CYTK, KRYS, and IBRX

Should you buy Enliven Therapeutics stock or one of its competitors? MarketBeat compares Enliven Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enliven Therapeutics include Abivax (ABVX), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Krystal Biotech (KRYS), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does Enliven Therapeutics compare to Abivax?

Enliven Therapeutics (NASDAQ:ELVN) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

In the previous week, Abivax had 23 more articles in the media than Enliven Therapeutics. MarketBeat recorded 27 mentions for Abivax and 4 mentions for Enliven Therapeutics. Abivax's average media sentiment score of 0.06 beat Enliven Therapeutics' score of -0.03 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	4 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Neutral

Enliven Therapeutics presently has a consensus target price of $61.80, suggesting a potential upside of 78.05%. Abivax has a consensus target price of $130.08, suggesting a potential upside of 28.12%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Enliven Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Enliven Therapeutics' return on equity of -21.04% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Abivax	N/A	-99.02%	-70.26%

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Enliven Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Summary

Enliven Therapeutics beats Abivax on 9 of the 14 factors compared between the two stocks.

How does Enliven Therapeutics compare to Praxis Precision Medicines?

Enliven Therapeutics (NASDAQ:ELVN) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Praxis Precision Medicines had 22 more articles in the media than Enliven Therapeutics. MarketBeat recorded 26 mentions for Praxis Precision Medicines and 4 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of -0.03 beat Praxis Precision Medicines' score of -0.10 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market.

Enliven Therapeutics presently has a consensus price target of $61.80, suggesting a potential upside of 78.05%. Praxis Precision Medicines has a consensus price target of $572.72, suggesting a potential upside of 125.48%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95

Enliven Therapeutics has higher earnings, but lower revenue than Praxis Precision Medicines. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Praxis Precision Medicines	$8.55M	828.25	-$303.27M	-$13.37	N/A

Enliven Therapeutics' return on equity of -21.04% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Praxis Precision Medicines beats Enliven Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Enliven Therapeutics (NASDAQ:ELVN) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, Cytokinetics had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 9 mentions for Cytokinetics and 4 mentions for Enliven Therapeutics. Cytokinetics' average media sentiment score of 0.10 beat Enliven Therapeutics' score of -0.03 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics has lower revenue, but higher earnings than Cytokinetics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	101.03	-$784.96M	-$6.84	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Cytokinetics currently has a consensus target price of $99.30, indicating a potential upside of 38.92%. Enliven Therapeutics has a consensus target price of $61.80, indicating a potential upside of 78.05%. Given Enliven Therapeutics' higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

95.1% of Enliven Therapeutics shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cytokinetics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Enliven Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Summary

Cytokinetics beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Enliven Therapeutics compare to Krystal Biotech?

Enliven Therapeutics (NASDAQ:ELVN) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Enliven Therapeutics presently has a consensus price target of $61.80, indicating a potential upside of 78.05%. Krystal Biotech has a consensus price target of $324.11, indicating a potential upside of 7.68%. Given Enliven Therapeutics' higher possible upside, equities analysts plainly believe Enliven Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has a net margin of 53.92% compared to Enliven Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Krystal Biotech	$389.13M	22.80	$204.83M	$7.48	40.24

Enliven Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

In the previous week, Krystal Biotech had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 5 mentions for Krystal Biotech and 4 mentions for Enliven Therapeutics. Krystal Biotech's average media sentiment score of 0.43 beat Enliven Therapeutics' score of -0.03 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Krystal Biotech beats Enliven Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to ImmunityBio?

Enliven Therapeutics (NASDAQ:ELVN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Enliven Therapeutics presently has a consensus price target of $61.80, indicating a potential upside of 78.05%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 105.20%. Given ImmunityBio's higher possible upside, analysts plainly believe ImmunityBio is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 69.5% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Enliven Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market.

Enliven Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
ImmunityBio	-606.15%	N/A	-59.53%

Enliven Therapeutics has higher earnings, but lower revenue than ImmunityBio. Enliven Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
ImmunityBio	$113.29M	63.97	-$351.40M	-$0.85	N/A

In the previous week, ImmunityBio had 4 more articles in the media than Enliven Therapeutics. MarketBeat recorded 8 mentions for ImmunityBio and 4 mentions for Enliven Therapeutics. ImmunityBio's average media sentiment score of 0.15 beat Enliven Therapeutics' score of -0.03 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

ImmunityBio beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELVN vs. The Competition

Export

Metric	Enliven Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.16B	$2.98B	$6.48B	$12.46B
Dividend Yield	N/A	1.70%	2.67%	5.34%
P/E Ratio	-20.78	17.86	23.93	23.64
Price / Sales	N/A	286.03	517.31	112.52
Price / Cash	N/A	56.21	42.35	57.17
Price / Book	4.48	3.83	9.73	6.37
Net Income	-$103.69M	$75.85M	$3.56B	$337.36M
7 Day Performance	-12.28%	-4.88%	-3.19%	-3.07%
1 Month Performance	-16.52%	-5.87%	-0.11%	0.37%
1 Year Performance	62.42%	18.98%	25.29%	27.87%

Enliven Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELVN Enliven Therapeutics	3.0198 of 5 stars	$34.71 -2.2%	$61.80 +78.0%	+59.2%	$2.16B	N/A	N/A	50	Analyst Forecast
ABVX Abivax	3.4658 of 5 stars	$126.41 +3.6%	$137.15 +8.5%	+1,201.9%	$10.07B	N/A	N/A	61	Analyst Forecast Options Volume
PRAX Praxis Precision Medicines	3.1984 of 5 stars	$350.60 +2.0%	$592.67 +69.0%	+540.0%	$9.77B	$8.55M	N/A	110	News Coverage Analyst Forecast Analyst Revision
CYTK Cytokinetics	2.8375 of 5 stars	$76.29 -0.8%	$99.30 +30.2%	+123.0%	$9.49B	$88.04M	N/A	250
KRYS Krystal Biotech	3.1592 of 5 stars	$302.68 +1.1%	$324.11 +7.1%	+133.1%	$8.92B	$389.13M	40.47	210	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELVN) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enliven Therapeutics (ELVN) Competitors

ELVN vs. ABVX, PRAX, CYTK, KRYS, and IBRX

How does Enliven Therapeutics compare to Abivax?

Summary

How does Enliven Therapeutics compare to Praxis Precision Medicines?

Summary

How does Enliven Therapeutics compare to Cytokinetics?

Summary

How does Enliven Therapeutics compare to Krystal Biotech?

Summary

How does Enliven Therapeutics compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enliven Therapeutics (ELVN) Competitors

ELVN vs. ABVX, PRAX, CYTK, KRYS, and IBRX

How does Enliven Therapeutics compare to Abivax?

Does the media prefer ELVN or ABVX?

Do analysts rate ELVN or ABVX?

Which has higher valuation & earnings, ELVN or ABVX?

Is ELVN or ABVX more profitable?

Do institutionals & insiders hold more shares of ELVN or ABVX?

Which has more volatility and risk, ELVN or ABVX?

Summary

How does Enliven Therapeutics compare to Praxis Precision Medicines?

Does the media refer more to ELVN or PRAX?

Which has more volatility and risk, ELVN or PRAX?

Do analysts recommend ELVN or PRAX?

Which has preferable earnings & valuation, ELVN or PRAX?

Is ELVN or PRAX more profitable?

Do insiders & institutionals have more ownership in ELVN or PRAX?

Summary

How does Enliven Therapeutics compare to Cytokinetics?

Does the media favor CYTK or ELVN?

Which has higher earnings & valuation, CYTK or ELVN?

Do analysts prefer CYTK or ELVN?

Do institutionals & insiders believe in CYTK or ELVN?

Which has more volatility & risk, CYTK or ELVN?

Is CYTK or ELVN more profitable?

Summary

How does Enliven Therapeutics compare to Krystal Biotech?

Do insiders & institutionals believe in ELVN or KRYS?

Do analysts recommend ELVN or KRYS?

Is ELVN or KRYS more profitable?

Which has preferable earnings & valuation, ELVN or KRYS?

Which has more risk & volatility, ELVN or KRYS?

Does the media prefer ELVN or KRYS?

Summary

How does Enliven Therapeutics compare to ImmunityBio?

Do analysts prefer ELVN or IBRX?

Do insiders and institutionals have more ownership in ELVN or IBRX?

Which has more risk & volatility, ELVN or IBRX?

Is ELVN or IBRX more profitable?

Which has stronger valuation & earnings, ELVN or IBRX?

Does the media prefer ELVN or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools